Arcus, Gilead Drop A2R Inhibitor in Prostate Cancer After Glimpsing Early Data

Arcus Biosciences and Gilead have decided not to advance their A2R inhibitor in prostate cancer after taking a look at some early clinical data. The two companies are studying the candidate, called etrumadenant, in trials of various cancers in combination with chemo and other drugs.